Precursor B-cell acute lymphoblastic leukemia is a fast-growing leukemia that affects early B cells in bone marrow. It’s both more common and has a better outlook in children. Leukemia is a type ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

One such type is Acute Lymphoblastic Leukemia (ALL), which is characterised by the uncontrolled proliferation of immature white blood cells known as lymphoblasts. This condition can disrupt normal ...

The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens ...

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approval was based on results from the ...

Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial.The study was put on hold due to grade 5 events among patients who received inotuzumab ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

CD37, a surface protein present on most acute myeloid leukemia (AML ... with normal hematopoietic stem cells, peripheral blood mononuclear cells, and AML cell lines. Analysis included ...

The CAR T-cells then recognise and attack the cancer cells. Some children and young people up the age of 25 years have a type of CAR T-cell therapy called tisagenlecleucel (Kymriah). It is for a type ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.